Monoclonal Antibodies Drive Pathogenesis in Heparin-Induced Thrombocytopenia: NEJM

Heparin-induced thrombocytopenia (HIT) is a serious immune-mediated adverse effect of heparin therapy, characterised by thrombocytopenia and a high risk of thrombotic complications. Despite established clinical and laboratory diagnostic criteria, the precise immunopathogenesis of HIT remains incompletely understood. The identification of specific pathogenic antibodies could provide insights into disease mechanisms and guide the development of targeted diagnostic and therapeutic strategies.

A recent observational study evaluated nine patients with confirmed HIT to determine the presence, clonality, and pathogenic potential of heparin-dependent antibodies. Using advanced immunologic assays, researchers detected monoclonal antibodies in all patients, establishing a consistent link between these antibodies and HIT pathogenesis. Functional assays confirmed that these monoclonal antibodies were capable of activating platelets in a heparin-dependent manner, directly contributing to the thrombotic phenotype observed clinically. The study highlights that HIT may not be driven by polyclonal antibody responses, as previously thought, but rather by the action of specific monoclonal pathogenic antibodies. This discovery has multiple clinical implications. First, detection of monoclonal HIT antibodies may allow for earlier and more precise diagnosis, improving patient management and reducing the risk of thrombotic complications. Second, the identification of a monoclonal antibody target offers a potential avenue for developing targeted therapies that neutralize pathogenic antibodies without broadly suppressing immune function. Finally, these findings may inform risk stratification, helping clinicians identify patients at higher likelihood of severe HIT-related outcomes. Overall, this research advances the understanding of HIT immunopathogenesis and provides a foundation for the next generation of diagnostic and therapeutic approaches. The findings support further exploration into monoclonal antibody-targeted strategies, which could transform the clinical management of this high-risk condition and reduce morbidity associated with heparin therapy.

Keywords
heparin-induced thrombocytopenia, HIT, monoclonal antibodies, immunopathogenesis, thrombosis, platelet activation, diagnostics, targeted therapy, immune-mediated, NEJM

Reference
Greinacher, A., Selleng, K., Warkentin, T. E., et al. (2025). Monoclonal antibodies in patients with heparin-induced thrombocytopenia. New England Journal of Medicine, 393, 1782–1793. https://doi.org/10.1056/NEJMoa2507175

Powered by WPeMatico

Early Metabolic Patterns in Prediabetes Help Predict Long-Term Complications: Study

A new long-term study published in the journal of Diabetes Care revealed that early metabolic patterns in prediabetes can forecast the risk of developing severe complications decades later in individuals at risk of type 2 diabetes (T2D). The findings highlight that while many people with prediabetes remain metabolically stable, specific subgroups face sharply increased risks of vision, nerve, kidney, and heart problems.

The research analyzed clinical data from 1,732 participants, tracking 12 health-related traits including blood sugar levels, insulin resistance, kidney function, blood pressure, and cholesterol. To make sense of these long-term patterns, the team applied tensor decomposition to uncover longitudinal trajectories, and Gaussian mixture modeling to classify patients into clusters. Complication risks for each group were then compared using regression analyses.

The study identified 4 clear clusters of prediabetes progression:

  • Cluster 1 and Cluster 2 (73% of participants): These individuals maintained stable blood sugar, blood pressure, and lipid levels over time. While nearly half in Cluster 1 and more than two-thirds in Cluster 2 eventually developed T2D, their risk of serious vascular complications remained low. Thus, diabetes progression did not automatically translate into organ damage for most.
  • Cluster 3 (12% of participants): This group underwent the sharpest increase in insulin resistance and blood sugar. Nearly all (92%) went on to develop T2D. Also, the complication rates soared which showed an almost 9-fold increase in risk of retinopathy (eye disease) and more than triple the risk of neuropathy (nerve damage) compared to other groups.
  • Cluster 4 (15% of participants): Unlike Cluster 3, members of this group displayed early kidney stress, marked by microalbuminuria, even before developing diabetes (73% eventually did). Their kidney function steadily declined, and they were twice as likely to experience cardiovascular events such as heart attacks or strokes, despite having cholesterol levels similar to the lower-risk groups.

The study points to a critical shift in how prediabetes should be viewed. Roughly two-thirds of individuals appear “metabolically resilient,” showing low long-term complication rates even if they progress to diabetes. However, the remaining third exhibit early metabolic signals that precede specific, severe complications.

Overall, this research emphasized that preventive strategies must be tailored accordingly. For those with early kidney issues, the window to prevent cardiovascular disease may actually come before diabetes fully develops. Also, aggressive management of insulin resistance in high-risk individuals could stave off vision and nerve damage.

Source:

Kobayashi, E., Linden-Santangeli, N. J., Chan, N., Toomey, C. B., Mudaliar, S., Temprosa, M., Edelstein, S., Goyal, R., Rangamani, P., Majithia, A. R., Diabetes Prevention Program Research Group, Bray, G. A., Gadde, K. M., Culbert, I. W., Arceneaux, J., Chatellier, A., Dragg, A., Champagne, C. M., Duncan, C., … Hivert, M.-F. (2025). Longitudinal metabolic trajectories in Diabetes Prevention Program participants reveal subgroups with varying micro- and macrovascular complication risks. Diabetes Care,. https://doi.org/10.2337/dc25-0866

Powered by WPeMatico

FFR-Guided Complete Revascularization Beneficial in NSTEMI With Multivessel Disease: JAMA

Netherlands: Researchers have found in a new study that fractional flow reserve–guided complete revascularization during the index procedure is effective for patients with non–ST-segment elevation myocardial infarction (NSTEMI) and multivessel disease.

The trial, published in JAMA and led by Dr. Tobias F.S. Pustjens from the Department of Cardiology at Zuyderland Medical Centre, the Netherlands, provides important clinical evidence on the benefits of treating all significant coronary lesions, rather than focusing solely on the culprit artery, in patients with NSTEMI.
The SLIM (Fractional Flow Reserve–Guided Complete Versus Culprit-Only Revascularization in NSTEMI and Multivessel Disease) randomized clinical trial included 478 patients across nine European hospitals. Participants had a mean age of nearly 66 years, and more than 70% were men. All patients underwent successful treatment of the culprit lesion and were then randomized to either FFR-guided complete revascularization or culprit-only revascularization, with staged procedures allowed in the culprit-only group.
Based on the study, the researchers reported the following findings:
  • The primary composite outcome of all-cause mortality, nonfatal myocardial infarction, any revascularization, and stroke within one year occurred in 5.5% of patients in the complete revascularization group versus 13.6% in the culprit-only group.
  • This corresponded to a 62% relative risk reduction (HR, 0.38).
  • The difference was mainly driven by lower rates of repeat revascularization in the complete revascularization arm (3.0% vs 11.5%; HR, 0.24).
  • Net adverse clinical events were also significantly reduced (6.3% vs 15.3%; HR, 0.39).
  • No significant differences were observed in individual outcomes such as death or myocardial infarction when analyzed separately.
According to the authors, these findings suggest that addressing all physiologically significant lesions in a single setting can improve outcomes and reduce the need for future interventions. The results lend support to adopting an FFR-guided complete revascularization approach in NSTEMI patients with multivessel disease.
Still, the study had several limitations. It was not sufficiently powered to detect differences in individual outcomes such as cardiovascular death or myocardial infarction, which are being further explored in the ongoing COMPLETE-NSTEMI trial. The open-label design could have influenced treatment decisions in the culprit-only group, and the absence of data on patients who were screened but not enrolled raises concerns about selection bias. Additionally, identifying the culprit lesion in NSTEMI can be complex, and the definition of significant stenosis at a 50% threshold may vary across clinical practices.
Despite these challenges, the investigators concluded that FFR-guided complete revascularization provides meaningful clinical benefit in reducing composite cardiovascular events. The advantage was mainly driven by fewer repeat procedures, highlighting the value of treating all significant lesions upfront.
“The SLIM trial contributes to evolving evidence in the management of NSTEMI with multivessel disease, offering important insights for clinicians weighing complete versus selective intervention strategies,” the authors concluded.
Reference:
Pustjens TF, Veenstra L, Camaro C, et al. Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease: The SLIM Randomized Clinical Trial. JAMA. Published online August 31, 2025. doi:10.1001/jama.2025.16189

Powered by WPeMatico

Baricitinib not linked to increased VTE Risk in Alopecia Areata Patients: Study

A new study published in the International Journal of Dermatology revealed that alopecia areata patients treated with baricitinib had no reported thrombotic events over 6 months, indicating no increased risk of venous thromboembolism (VTE) in this population.

Based on post-marketing data from patients with rheumatoid arthritis (RA) receiving tofacitinib, the European Medicines Agency (EMA) released an advisory in January 2023 on the risk of VTE associated with Janus kinase inhibitors (JAKi) in chronic inflammatory disorders. Given that RA is a recognized independent risk factor for VTE, this might be biased.

Additionally, the effects of JAKi differ due to differences in enzyme selectivity. In this investigation, VTE risk factors were examined in a cohort of AA patients who were eligible for baricitinib therapy. Additionally, any changes in laboratory VTE markers following 6 months of baricitinib treatment were evaluated.

The patients with moderate-to-severe AA who were ≥ 18 years old, suitable for therapy with baricitinib 4 mg, and who presented to the department consecutively between July 2023 and July 2024 were included in a prospective observational research. During the screening appointment, baseline clinical and demographic information was gathered.

Patients with major (a prior VTE episode) or minor (smoking status, active malignancies, family history of VTE, prior thrombophlebitis, recent trauma or fractures, prolonged immobilization, major recent surgeries, use of estrogen-progestin contraceptives, and recurrent miscarriages) clinical risk factors for VTE were also identified through a comprehensive medical history check. Additionally, baseline and 6-month therapy levels were assessed for antiphospholipid antibodies (lupus anticoagulant, anti-cardiolipin, and anti-β2 glycoprotein I), protein C, antithrombin III, homocysteine, protein S, and factor VIII.

After being evaluated for baricitinib therapy eligibility, 47 individuals with moderate-to-severe AA were included to the trial. Based on the previously published criteria, none of the screened patients showed a contraindication to the therapy. In terms of clinical VTE risk factors at baseline, 1 patient (2.1%) had a history of superficial thrombophlebitis, 5 women (10.6%) were taking combination estrogen-progestin contraceptives, and 8 out of 47 patients (17%) were heavy smokers.

There were no significant risk factors in any of the patients. Although two patients (4.2%) had bone fractures, which are recognized clinical risk factors for VTE, there were no thrombotic events while on baricitinib. Laboratory tests conducted on 37 out of 47 patients after 6 months of continuous medication revealed no changes in the majority of patients. Overall, these results imply that the risk of experiencing adverse events from VTE might be decreased for individuals who are eligible for baricitinib therapy.

Source:

Caldarola, G., Ferretti, A., Pinto, L. M., Di Gennaro, L., De Luca, E., Falco, G. M., De Simone, C., De Cristofaro, R., & Peris, K. (2025). No increased risk of thromboembolic events during 6-month treatment with baricitinib in patients with alopecia areata. International Journal of Dermatology, ijd.70051. https://doi.org/10.1111/ijd.70051

Powered by WPeMatico

Extensive Gastric Atrophy Linked to Higher Risk of Esophageal Cancer: Study

Researchers have established in a new study that extensive gastric atrophy (GA) greatly increases the risk of esophageal squamous cell carcinoma (ESCC) development. This new large Japanese cohort study yields more compelling evidence, demonstrating that open-type GA independently elevates the risk of ESCC, even after risk factor adjustment for established risk factors including age, sex, alcohol, and smoking. The study was published in Digestive Endoscopy journal by Kenta W. and colleagues.

The investigation was a retrospective nationwide cohort study that involved 17 health check-up centers in Japan. There were 33,461 participants who received endoscopy from 2013 to 2017 and had at least one follow-up endoscopy up to December 2022. GA was assessed endoscopically and was classified into three groups: atrophy-free, closed-type GA, and open-type GA. The incidence of ESCC was evaluated by Kaplan-Meier survival analysis and Cox regression models by the researchers. Multivariable adjustment was done by considering key confounders such as age, gender, drinking, and smoking.

Results

  • Of the 33,461 participants, 17,398 (52.0%) were atrophy-free, 8257 (24.7%) had closed-type GA, and 7804 (23.3%) had open-type GA.

  • During a median follow-up duration of 6 years, 77 new ESCC cases were newly diagnosed.

The incidence rates were shown to vary significantly among the groups:

  • Atrophy-free group: 24 cases (0.024% per year)

  • Closed-type GA group: 15 cases (0.031% per year)

  • Open-type GA group: 38 cases (0.089% per year)

  • Statistical analysis showed that open-type GA had a strong correlation with increased ESCC risk (p < 0.001).

  • In a model adjusted for known risk factors, open-type GA was an independent risk factor with an adjusted hazard ratio of 2.72 (95% CI: 1.58–4.69).

  • Closed-type GA did not correlate with ESCC after adjustment.

This huge Japanese cohort study presents new evidence that severe gastric atrophy of the open-type is causally associated with a higher risk of esophageal squamous cell carcinoma. Closed-type GA was not associated with such risk, suggesting that atrophy severity is crucial. The results highlight the need to recognize GA, especially open-type, as a possible marker of ESCC risk and stress the necessity for strict long-term follow-up in this group.

Reference:

Watanabe K, Fukuda S, Kubota D, et al. Potentially Causal Associations Between Extensive Gastric Atrophy and Esophageal Squamous Cell Carcinoma: A Nationwide Retrospective Cohort Study in Japan. Dig Endosc. Published online August 26, 2025. doi:10.1111/den.70019

Powered by WPeMatico

Worse outcomes with aspirin in high-risk chronic coronary syndrome patients who require long-term anticoagulation: ESC Study

Adding aspirin increased the risk of cardiovascular events, death and major bleeding in high-risk patients with chronic coronary syndrome (CCS) who had prior stenting and were receiving long-term chronic oral anticoagulation (OAC), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

Explaining the rationale of the AQUATIC trial, its Principal Investigator, Professor Martine Gilard from Hospital Cavale Blanche, Brest, France, said: “After stent implantation, many patients with CCS (stable coronary artery disease) are at high risk for future cardiovascular events due to conditions including diabetes, chronic kidney disease and diffuse multivessel disease, and some require long-term anticoagulation, particularly due to atrial fibrillation (AF). Managing the risk of further cardiovascular events in these patients is challenging and there is limited trial evidence to guide the optimal antithrombotic strategy. We designed the AQUATIC trial to formally test the efficacy and safety of adding aspirin to OAC, a combination that is commonly used for this high-risk population in clinical practice.”

This was a double-blind, placebo-controlled, parallel-group, randomised trial conducted at 51 centres in France. Eligible patients had CCS and stent implantation (>6 months before), were at high atherothrombotic risk and required long-term OAC for any reason (mainly AF). High atherothrombotic risk was defined as either a history of percutaneous coronary intervention (PCI) during an acute coronary syndrome (ACS) (with ≥1 stent(s) >6 months) or history of PCI (>6 months) outside the context of ACS but with high-risk features such as diabetes, chronic kidney disease, diffuse multivessel disease (involvement of three coronary vessels), history of complex PCI or peripheral artery disease. Patients were randomised 1:1 to aspirin or placebo on top of OAC (either a direct OAC or vitamin K antagonists). The primary efficacy endpoint was a composite of cardiovascular death, myocardial infarction, stroke, systemic embolism, coronary revascularisation and acute limb ischaemia. The key secondary safety endpoint was major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) definition.

The trial was stopped early on the advice of the independent Data Safety Monitoring Board after a median follow-up of 2.2 years due to an excess of all-cause mortality in the aspirin group. The 872 patients randomised had a mean age of 72 years and 14.5% were male.

The primary efficacy outcome occurred in significantly more patients in the aspirin group than the placebo group (16.9% vs. 12.1%; adjusted hazard ratio [HR] 1.53; 95% confidence interval [CI] 1.07 to 2.18; p=0.019). All-cause death also occurred in significantly more patients with aspirin vs. placebo (13.4% vs. 8.4%; adjusted HR 1.72; 95% CI 1.14 to 2.58; p=0.010).

The risk of major bleeding was more than three-fold higher in the aspirin group than the placebo group (10.2% vs. 3.4%; HR 3.35; 95% CI 1.87 to 6.00; p<0.0001).

A total of 467 and 395 serious adverse events were reported in the aspirin and placebo groups, respectively.

In conclusion, Professor Gilard said: “Among patients with CCS at high atherothrombotic risk who require OAC therapy, aspirin significantly increased the risk of major cardiovascular events, all-cause mortality and major bleeding, and its use should be discouraged. Other studies have investigated antithrombotic therapy for stable coronary artery disease and AF, 2,3 but this is the first randomised trial to include patients who had prior stenting and with high atherothrombotic risk − event rates were around seven times higher in AQUATIC than in previous trials. Our findings can now be considered in future ESC Guidelines to build on current recommendations, which are based on expert consensus.”

Reference:

Gilles Lemesle, Romain Didier, Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation, New England Journal of Medicine, DOI: 10.1056/NEJMoa2507532.

Powered by WPeMatico

Uterine Manipulators Enhance Laparoscopic Rectal Surgery Outcomes: Study

A recent study published in BMC Surgery found that uterine manipulators improve surgical exposure in laparoscopic rectal procedures in women without compromising oncological or perioperative outcomes.

The research analyzed female patients undergoing laparoscopic rectal resection for benign and malignant conditions, comparing those in whom uterine manipulators were used with those operated on without them. Surgeons reported enhanced visualization of the deep pelvis, which is often restricted in women due to uterine mobility and narrower pelvic dimensions. Improved access allowed for precise dissection around critical structures such as the rectum, ureters, and neurovascular bundles, facilitating safer and more efficient surgery. Importantly, the use of uterine manipulators did not significantly increase operative time, intraoperative blood loss, or postoperative complications. Oncological parameters—including total mesorectal excision quality, lymph node harvest, and circumferential resection margin—remained consistent across both groups, confirming that manipulator use does not compromise cancer-related outcomes. Functional outcomes, such as urinary and sexual function, were similarly unaffected, reinforcing the safety of this approach.

The authors emphasize that uterine manipulators can be particularly beneficial in challenging pelvic dissections, such as low rectal tumors or in patients with obesity or a narrow pelvis. While the findings support routine consideration of manipulators in female laparoscopic rectal surgery, they also highlight the importance of surgeon experience and familiarity with the device to maximize benefits. The study concludes that uterine manipulators serve as a valuable adjunct, providing enhanced exposure and operative confidence while maintaining safety and oncological integrity. Further randomized trials and long-term follow-up studies are suggested to assess additional outcomes, including patient-reported quality of life and potential impacts on postoperative recovery. Overall, this research underscores the potential for uterine manipulators to improve technical feasibility and precision in minimally invasive rectal surgery for women.

Reference:
Zhu, Y., Wang, X., Liu, H., & Chen, L. (2025). Uterine manipulators enhance surgical exposure in laparoscopic rectal cancer surgery in women without affecting oncological or perioperative outcomes. BMC Surgery, 25, 189. https://doi.org/10.1186/s12893-025-03078-2 [API]

Keywords: uterine manipulator, laparoscopic rectal surgery, female pelvic anatomy, surgical exposure, pelvic dissection, oncological outcomes, BMC Surgery

Powered by WPeMatico

’12k too low’: FMGs urge UP govt for stipend hike

New Delhi: The foreign medical graduates have urged the Uttar Pradesh Government to increase the stipend for medical graduates from abroad who are undergoing internship in the State.

Currently, the FMGs undergoing internship get Rs 12,000 per month as their stipend. Pointing out that the stipend for FMG interns in Bihar was recently raised to Rs 27,000 per month, the All FMGs Association (AFA) has demanded an increase in the stipend amount in Uttar Pradesh as well.

Highlighting the issue, AFA mentioned in an X post, “I respectfully request @CMOfficeUP @myogiadityanath @brajeshpathakup ji to consider increasing the stipend for intern doctors in Uttar Pradesh, as it is currently lower than the daily wage for laborers and neighbor states.”

Medical Dialogues had earlier reported that, offering respite to the MBBS, BDS, and AYUSH interns in Bihar, the State Government announced a stipend hike. The State Government announced that the MBBS, BDS, Ayurvedic, Unani, and Homoeopathy Interns in the government medical colleges, Patna Dental College and other institutes across the State would get Rs 27,000 per month. Previously, they used to get Rs 20,000 per month as their stipend.

Also Read: Bihar Govt approves stipend hike: MBBS, BDS, AYUSH, FMG interns to get Rs 27k per month

Apart from this, the State had also announced to give a Rs 27,000 monthly stipend to the Foreign Medical Graduates (FMGs) undergoing mandatory internship in the State’s Government Medical Colleges.

Referring to this, Dr. Kaushal from All FMGs Association (AFA) told Medical Dialogues, “Although Uttar Pradesh is more developed than Bihar and some neighbouring states, they still offer only 12k to their MBBS interns, which includes FMGs and IMGs interns. Recently, Bihar has raised the stipend from 20 to 27k. Delhi is already paying a nearly 30k stipend. States like Odisha, Assam, and West Bengal pay nearly 40k. But interns in Uttar Pradesh are getting such a low stipend.”

“AFA urges CM and the health minister sir to respond on this matter and understand the need of interns doctors who work tirelessly and increase the stipend in Uttar Pradesh,” he added.

Meanwhile, the Indian Medical Graduates in Uttar Pradesh have also been demanding a stipend hike. Medical Dialogues had earlier reported that MBBS interns in Uttar Pradesh recently protested against this on the social media platform X. Currently, the medical interns in Uttar Pradesh receive Rs 12,000 per month as their stipend, which, the students have claimed, is the lowest stipend in the country.

Also Read: UP MBBS interns launch protest storm on X demanding stipend hike

Powered by WPeMatico

Death of 2 newborns at Indore Hospital: NHRC seeks Action Taken Report

Bhopal: Taking cognisance of the deaths of two newborns allegedly bitten by rats at Indore’s government-run Maharaja Yeshwantrao (MY) Hospital, the National Human Rights Commission (NHRC) has issued notices to the Principal Secretary, Public Health and Medical Education Department, Madhya Pradesh government, and Indore District Collector, seeking an action taken report within 10 days.  

Medical Dialogues had reported that two newborns were bitten by rats inside the Neonatal Intensive Care Unit (NICU). One of the newborns, bitten over the weekend, passed away on Tuesday. The second infant admitted to the same neonatal intensive care unit (NICU) reportedly died after suffering injuries believed to be caused by a rat.

However, hospital authorities stated that the cause of death of the two infants was their critical medical condition, not the rat bite. They attributed their deaths to pneumonia and septicaemia, respectively. According to hospital officials, the reported rat bite resulted only in “minor scratches” on two fingers and was not a contributing factor in the fatality.

Also read- Another newborn dies amid rat bite allegations at Indore Hospital

While hospital authorities claimed that both newborns died due to pre-existing medical conditions, including congenital deformities, families and civil society groups have alleged gross negligence, as they claimed that the deaths are linked to alleged rat bites inside the hospital’s neonatal intensive care unit (NICU).

In support of the deceased infant’s families, a non-profit organisation, Network for Access to Justice, filed a complaint before the commission and sought immediate action against the responsible individuals and the urgent need for accountability, alleging that the families of the children have suffered irreparable loss.

While considering the matter, the commission in the notice said, “The complainant stated that this horrifying event highlights gross medical negligence and a complete failure to ensure basic hygiene and patient safety. Such a lapse not only breaches the trust of citizens in public healthcare but also constitutes a serious violation of the Right to Life and Health under Article 21 of the Constitution.”

In its notice, the NHRC has directed authorities that the allegations levelled in the complaint be inquired into, and asked to submit an “action taken report within 10 days” for perusal of the commission.

The Commission further stated, “Immediate measures must be taken to improve sanitation, pest control, and overall safety standards in government hospitals across the State. The allegations made in the complaint prima facie seem to be serious violations of the human rights of the victims.”

Speaking to The Hindu, NHRC member Priyank Kanoongo said, “Such incidents revealed a pathetic state of affairs at government hospitals in the State, while also pointing out that no action has been taken against any senior official in the matter.

“If the action is only taken against a company that provides manpower and some nursing staff, nothing is going to improve. For the system to be fixed, accountability has to be fixed from the top,” he added. 

More serious accusations

The Jai Adivasi Yuva Shakti (JAYS), a tribal organisation, on Monday claimed rats had gnawed four fingers of one of the deceased infants and accused the medical facility’s administration of lying and misleading everyone. They demanded suspension of the hospital superintendent and other senior officials, along with registration of a case of culpable homicide not amounting to murder.

If the demand is not met by Monday evening, the tribal community would launch a major agitation, JAYS national president Lokesh Mujalda warned.

Two newborn girls, who had been bitten by rats in the hospital’s ICU, died recently, raising questions about the institution’s functioning.

One of them, the daughter of Devram from Dhar district, who was admitted to the hospital with congenital deformities, died after the rat attack, Mujalda claimed while talking to PTI. The body was handed over to the family in a plastic bag after the post-mortem on Saturday evening, he said.

When the packing was removed before the funeral, the family was devastated and enraged to notice that four fingers on one hand of the baby had allegedly been gnawed by rats, Mujalda said.

He accused the MYH administration of misleading everyone by initially claiming the baby had only suffered minor injuries to her fingers due to rat bites.

On Saturday, JAYS functionaries staged a protest at the hospital with the bereaved parents seeking compensation of Rs 1 crore each for the families of the two infants, as well as registration of a culpable homicide case against senior officials.

“The district administration has assured us that the necessary steps will be taken to suspend senior officials of MYH and register an FIR against them. If this demand is not fulfilled within 10 days, another protest will be staged by us at MYH,” Mujalda had said.

The hospital administration has so far taken disciplinary action against six officials, including suspension and removal from posts, in connection with the deaths.

Also read- Rahul Gandhi slams PM Modi, State Govt over newborns’ death at Indore Hospital

Powered by WPeMatico

Massive MBBS Seats Vacant Across Indian Medical Colleges, reveals four-year report

Altogether 11,966 UG medical seats remained vacant in the last four years (starting from the academic year 2021-2022), revealed the data shared by the Union Minister of State for Health, Smt. Anupriya Patel in the Lok Sabha.

As per the data shared by the Union MoS Health, the highest number of vacancies was recorded during the academic year 2022-2023 when altogether 4,146 UG medical seats remained unfilled.

In 2021-2022, the total number of vacant seats was a minimum- altogether 2,012 seats remained vacant that year. Thereafter, the number of vacant seats doubled. The following year i.e. in 2023-2024, the number dropped to 2,959 and in 2023-2024, the number of vacant UG medical seats further got reduced to 2,849.

For more details, check out the full story on the link below:

Four-Year Report: Massive MBBS Seat Vacancies Across Indian Medical Colleges

Powered by WPeMatico